Health&Life Co

Health&Life Co Rule of 40

The Rule of 40 of Health&Life Co (1781.TWO) as of Nov 6, 2026 is -60.27 %. In the previous year, Rule of 40 was 21.71 % — a change of -377.64% (lower).

Rule of 40

-60.27 %

YoY

-377.64%

Last updated:

Rule of 40 of Health&Life Co is 2025 -60.27 % . Rule of 40 of Health&Life Co was 2024 21.71 % . It decreases by -377.64% lower compared to the previous year.

The Health&Life Co Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
6.32 TWD
Jan 1, 2019
-50.41 TWD
Jan 1, 2020
81.65 TWD
Jan 1, 2021
-7.06 TWD
Jan 1, 2022
-7.42 TWD
Jan 1, 2023
-31.28 TWD
Jan 1, 2024
21.71 TWD
Jan 1, 2025
-60.27 TWD
The Health&Life Co Rule of 40 history
YEARRule of 40YoY
-60.27 %-377.64%
21.71 %-169.41%
-31.28 %+321.61%
-7.42 %+5.06%
-7.06 %-108.65%
81.65 %-261.96%
-50.41 %-897.96%
6.32 %-122.78%
-27.74 %+38.15%
-20.08 %+865.82%
-2.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Health&Life Co Stock analysis

What does Health&Life Co do? Health&Life Co Ltd generates revenue through the manufacturing and distribution of cardiovascular disease, in-vitro diagnostics, and respiratory care products. The company's primary products include electronic sphygmomanometers such as blood pressure monitors, nebulizers, and blood glucose monitoring systems, which measure and record systolic and diastolic blood pressure and glucose levels. These products are sold domestically in Taiwan and internationally to overseas markets. The firm targets healthcare providers, clinics, and consumers seeking home health monitoring solutions for chronic conditions like hypertension and diabetes. The company's product portfolio focuses on electronic sphygmomanometers, which are essential for daily health monitoring. By offering devices that measure blood pressure and glucose levels, Health&Life Co Ltd caters to patients managing cardiovascular and metabolic diseases. The domestic market in Taiwan serves as a key sales channel, while overseas markets provide additional growth opportunities for the firm's diagnostic and respiratory care products. Health&Life Co Ltd's business model relies on direct sales of medical devices to healthcare institutions and end-users. The firm's electronic sphygmomanometers, including blood pressure monitors and blood glucose systems, are distributed through both domestic and international channels. This approach ensures consistent revenue streams from the ongoing demand for home health monitoring equipment among patients with chronic conditions. Health&Life Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Health&Life Co stock

Rule of 40 of Health&Life Co is -60.27 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Health&Life Co since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Health&Life Co

All Key Metrics — Health&Life Co